Boehringer invests $1.3B in Nerio for cancer push

Boehringer Ingelheim, a prominent German pharmaceutical company, has acquired California-based biotech firm Nerio Therapeutics. This acquisition includes access to a groundbreaking preclinical immune checkpoint inhibitor, marking a significant development in Boehringer's immuno-oncology pipeline.

The deal, valued at $1.3 billion, grants Boehringer Ingelheim the rights to Nerio’s small molecules designed to inhibit the protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2). These proteins function as immune checkpoints, and by inhibiting them, the immune system can be activated to combat cancer cells more effectively.

Boehringer Ingelheim aims to leverage this acquisition to develop a central component of its immuno-oncology portfolio, with the ultimate goal of enhancing cancer treatment outcomes for patients.

In its 2023 earnings report released in April, Boehringer Ingelheim set ambitious targets, including the launch of 25 new treatments by 2030. In June, the company shared promising phase 2 trial results for survodutide, co-developed with Zealand Pharma, in treating metabolic dysfunction-associated steatohepatitis (MASH). Survodutide is currently undergoing five phase 3 trials for obesity, with high hopes that it will become a leading treatment for both MASH and nonalcoholic steatohepatitis (NASH).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!